Company Overview and News

 
KLCI seen trending sideways, to remain in consolidation mode

2018-09-19 theedgemarkets
KUALA LUMPUR (Sept 20): The FBM KLCI is seen trending sideways today and hover around the 1,800-point level, in line with the overnight rally at most global markets.
1562 6888 5187 0180 0107 AXXTF GLOCF

 
Axiata, HB Global, Glomac, BToto, Eduspec, PanPages, Kim Teck Cheong and Salcon

2018-09-19 theedgemarkets
KUALA LUMPUR (Sep 19): Based on corporate announcements and news flow today, stocks in focus for Thursday (Sep 20) may include the following: Axiata Group Bhd, HB Global Ltd, Glomac Bhd, Berjaya Sports Toto Bhd, Eduspec Holdings Bhd, PanPages Bhd, Kim Teck Cheong Consolidated Bhd and Salcon Bhd.
1562 6888 5187 0180 0107 AXXTF GLOCF

 
Kim Teck Cheong says audit committee chairman quit over trade receivable dispute

2018-09-19 theedgemarkets
KUALA LUMPUR (Sept 19): Kim Teck Cheong Consolidated Bhd (KTC) said today the dispute which led to the resignation of the chairman of its audit and risk management committee recently was because the majority of the board of directors had agreed not to impair the trade receivables as the management was confident that they were recoverable.
0180 BSMAF 1818

 
Stock With Momentum: Kim Teck Cheong Consolidated

2018-09-04 theedgemarkets
Kim Teck Cheong Consolidated Bhd (+ve) Trading of shares in Kim Teck Cheong Consolidated Bhd (KTC) (fundamental: 0.15/3, valuation: 0.3/3) settled unchanged at 17.5 sen yesterday, valuing the company at RM89.3 million. It was the second time this year that trading of KTC shares triggered our momentum algorithm.
0180

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...